![](https://www.worldpharmatoday.com/images/nBanners/Docuvera-728x90.jpeg")
Tag: Coronavirus information (COVID-19)
Clinical Trials
Daiichi Sankyo begins phase 1 trial in Japan for nafamostat inhalation formulation to treat Covid-19
Daiichi Sankyo Company, Limited announced that it has initiated in Japan a first-in-human phase 1 trial for nafamostat inhalation formulation (DS-2319), which is being...
Press Releases
Celonic and CureVac Announce Agreement to Manufacture over 100 Million Doses of CureVac’s COVID-19 Vaccine Candidate, CVnCoV
CureVac N.V., a biopharmaceutical company developing a new class of transformative medicines based on messenger ribonucleic acid (mRNA) and Celonic Group, a premium biopharmaceutical...
News
Johnson Announces Advance Purchase Agreement with the African Vaccine Acquisition Trust for the Companys COVID-19 Vaccine Candidate
Janssen Pharmaceutica NV, one of the Janssen Pharmaceutical Companies of Johnson & Johnson, has entered into an agreement with the African Vaccine Acquisition Trust...
Clinical Trials
Humanigen Reports Positive Phase 3 Topline Results Improves Survival Without Need for Mechanical Ventilation in Hospitalized Patients With COVID-19
Humanigen, Inc., a clinical-stage biopharmaceutical company focused on preventing and treating an immune hyper-response called ‘cytokine storm’ with its lead drug candidate, lenzilumab, today...
Clinical Trials
Foresee Pharma Announces Dosing of First Patient in Phase 2/3 Clinical Trial of FP-025 for Treatment of COVID-19 Associated ARDS
Foresee Pharmaceuticals Co., Ltd. announced the initiation of patient dosing in the Phase 2/3 clinical trial of FP-025, its highly selective oral MMP-12 inhibitor,...
News
GSK to support manufacture of Novavax COVID-19 vaccine
GSK has reached an agreement in principle with Novavax and the UK Government Vaccines Taskforce to support manufacturing of up to 60 million doses...
Clinical Trials
Lilly, Vir And GSK Report Positive Topline Data From COVID-19 Trial Of Bamlanivimab With Vir-7831
Eli Lilly and Company, Vir Biotechnology, Inc. and GlaxoSmithKline plc announced topline data from the expanded Phase 2 BLAZE-4 trial studying low-risk adult patients...
Subscribe
- Never miss a story with notifications
- Gain full access to our premium content
- Browse free from up to 5 devices at once
Must read